HTG Molecular Diagnostics, Inc. (HTGM) Stock Is Rising Now

April 26, 2018 - By Linda Rogers

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Logo

The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) is a huge mover today! The stock increased 5.38% or $0.19 during the last trading session, reaching $3.72. About 1.92 million shares traded or 34.03% up from the average. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has declined 59.58% since April 26, 2017 and is downtrending. It has underperformed by 71.13% the S&P500.
The move comes after 7 months positive chart setup for the $105.48M company. It was reported on Apr, 26 by Barchart.com. We have $3.83 PT which if reached, will make NASDAQ:HTGM worth $3.16 million more.

Analysts await HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report earnings on May, 21. They expect $-0.22 EPS, up 69.86 % or $0.51 from last year’s $-0.73 per share. After $-0.15 actual EPS reported by HTG Molecular Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 46.67 % negative EPS growth.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Among 2 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics had 10 analyst reports since November 8, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, April 17 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Thursday, February 1. H.C. Wainwright maintained the stock with “Buy” rating in Friday, January 5 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, January 24. Canaccord Genuity maintained the stock with “Buy” rating in Monday, January 8 report. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) earned “Buy” rating by H.C. Wainwright on Wednesday, December 27. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 8. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating on Friday, March 23. H.C. Wainwright has “Buy” rating and $700 target. The company was maintained on Friday, January 5 by Canaccord Genuity. Canaccord Genuity maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) on Friday, March 23 with “Buy” rating.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $105.48 million. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: